J. Rosenberg
24 works · 4,376 citations · h-index 14
Top works
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
- IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
- Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma
- Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
- Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity
- Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment
- Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity
- Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma
- Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
- Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma
- The pharmacokinetics of rituximab following an intravitreal injection
- Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
- Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
- Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B cell lymphoma
- Monoclonal anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen: generation and characterization of anti-idiotype antibodies.
- IDEC-C2B8
- Concurrent Primary Vitreoretinal and Spinal Cord Lymphoma
- Cyclophosphamide responsive primary angiitis of the CNS in a 61-year-old female
- Direct complement lysis as a major effector mechanism in rituximab (anti-CD20) therapy of B cell lymphomas
- IDEC-C2B8 chimeric anti-CD20 antibody Safety and clinical activity in the treatment of patients with relapsed low-grade or follicular non-Hodgkins lymphoma